NeuroSphere-supported collaboration to develop new treatments for ALS

A new $1.7M collaboration between McGill University, Raya Therapeutic (Montreal) and Eikonizo Therapeutics (Cambridge, Massachusetts) will enable researchers to conduct clinical trials to assess the efficacy of six different drug candidates for the treatment of Amyotrophic Lateral Sclerosis (ALS).

This new project, led by Thomas Durcan of the Montreal Neurological Institute - Hospital, is funded through a CDQM SynergiQc program grant and made possible through contributions from the Ministère de l’Économie et de l’Innovation du Québec (MEI) and from McGill's Healthy Brains, Healthy Lives (HBHL). HBHL contributed $200,000 to the project.

Read the full press release about the project.